REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
13 hedge funds and large institutions have $19M invested in REVIVA PHARMA HLDGS INC in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.17% more ownership
Funds ownership: 0% → 1.17% (+1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$3.63M |
| 2 |
MSU
Mizuho Securities USA
New York
|
+$3.07M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$2.37M |
| 4 |
CFIC
City Financial Investment Company
London,
United Kingdom
|
+$2.37M |
| 5 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$2.01M |
Top Sellers
RVPH Hedge Fund Activity: Q4 2018 in Review
13 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q4 2018, worth a combined $19M.
Buyers outnumbered sellers: 13 funds opened new RVPH positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Oxford Asset Management, opening a new position worth an estimated $3.63M.
- 13 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q4 2018, up from 0 in Q3 2018.
- Funds reported $19M of REVIVA PHARMA HLDGS INC stock for Q4 2018.
- 13 funds opened new REVIVA PHARMA HLDGS INC positions in Q4 2018 and 0 closed out, a net change of +13 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q4 2018 was Oxford Asset Management, an estimated $3.63M added.
Based on aggregated 13F filings for Q4 2018.